The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Open accessAbstract
Summary Background: Outcomes for children with relapsed or refractory acute myeloid leukemia (AML) remain poor. The BCL-2 inhibitor venetoclax has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older, unfit adults with newly diagnosed AML. The aims of the present study were to determine the safety and explore the activity of venetoclax with standard and high-dose chemotherapy in pediatric patients with relapsed AML. Methods: Patients with relapsed or refractory AML or acute leukemia of ambiguous lineage who were 2–22 years old and who had adequate organ function and performance status were eligible. We tested the safety and activity of venetoclax (240 or 360mg/m2/day orally for 28 days) in combination with cytarabine (100mg/m2/dose IV every 12 hours for 20 doses or 1000mg/m2/dose IV every 12 hours for 8 doses) with or without idarubicin (12mg/m2 IV). The primary endpoint was the recommended phase 2 dose (RP2D) of venetoclax plus chemotherapy and the secondary endpoint was the proportion of patients treated at the RP2D who achieved complete remission (CR) or complete remission with incomplete count recovery (CRi). Analyses were done per protocol. The study was at ClinicalTrials.gov (NCT03194932). The primary objective has been reached and the study is enrolling to address exploratory objectives. Findings: Thirty-eight patients were enrolled from July 1, 2017 to July 2, 2019, with a median follow-up of 7.1 months (IQR 5.1–11.2). The RP2D of venetoclax was 360mg/m2 (600mg max) combined with cytarabine (1000mg/m2/dose for 8 doses) with or without idarubicin (12mg/m2 as a single dose). Overall responses were observed in 24 (69%) of 35 evaluable patients, including 16 CR (11 MRD negative), 4 CRi (2 MRD negative), and 4 PR. Among the 20 patients treated at the RP2D 14 (70%) achieved CR or CRi and 16 (80%) CR/CRi/PR. The most common grade 3–4 adverse events were febrile neutropenia (25 patients), bloodstream infections (6 patients), and invasive fungal infections (6 patients). Treatment-related death occurred in only one patient. Interpretation: The safety and activity of venetoclax plus chemotherapy in patients with heavily pre-treated, relapsed and refractory AML suggests that this combination should be tested in newly diagnosed patients with high-risk AML. Funding: ALSAC, AbbVie, Gateway for Cancer Research, National Institutes of Health CA21765
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Abbreviated instrument to measure hope: development and psychometric evaluation
Herth, K. (1992) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.1992.tb01843.x · Cited by 1,109 · cited 1×
“Hopefulness and optimism were assessed using the Herth Hope Index (HHI),(15) in adolescents and young adults (13 years and older) as well as their parents.”
MethodWei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Self-citation
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., Leonard, J., Colace, S. I., Khaw, S. L., Fleming, S. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1465 · Cited by 302
Self-citationMeasurable Residual Disease in High-Risk Acute Myeloid Leukemia
Cluzeau, T., Lemoli, R. M., McCloskey, J., & Cooper, T. (2022) · Cancers · doi:10.3390/cancers14051278 · Cited by 13
“tients achieved CR or CRi, 13 of whom achieved MRD negativity (based on flow cytometry by central assessment) [49].”
BackgroundVenetoclax for paediatric acute myeloid leukaemia: a step forward
Aplenc, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30136-4 · Cited by 1
Metadata
- Authors
- Karol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., Kim, S. Y., Salem, A. H., Palenski, T., Lacayo, N. J., Pui, C.-H., Opferman, J. T., & Rubnitz, J. E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 551-560
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3011638072
- Cited by
- 163
- References
- 3
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30060-7
- The paper
- Karol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., Kim, S. Y., Salem, A. H., Palenski, T., Lacayo, N. J., Pui, C.-H., Opferman, J. T., & Rubnitz, J. E. (2020). Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30060-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.